View More View Less
  • 1 Division of Virology National Center for Epidemiology Albert Flórián utca 2-6 H-1097 Budapest Hungary
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Despite intensive efforts in recent decades to develop preventive or therapeutic vaccines against diseases caused by herpes simplex virus (HSV), or varicella-zoster virus (VZV), members of the Alpha herpes virinae subfamily of human herpes viruses,a safe and efficient vaccine has been approved for commercial development only against VZV. The VZV vaccine contains a live attenuated strain, OKA. It consists of amixture of at least 13 subpopulations of viruses, all with deletions, insertions or mutations in the genome; the most common mutations are observed in the open reading frame 62 (ORF62). Experience over more than 30 years in Japan, the USA and other countries where VZV vaccination is provided has demonstrated that the vaccine is safe and the effectiveness of two doses compared to unvaccinated children is 98–99%. When administered in a higher dose to stimulate the declining cell-mediated immunity, the same vaccine has been shown to reduce the incidence and severity of herpes zoster in immunocompetent individuals older than 60 years. Vaccination of immuno-compromised subjects with this VZV vaccine is problematic and various strategies need to be explored. Differences in the pathomechanisms of infection, latency and immune evasion of VZV and HSV, together with host genetic factors, may explain the availability of the successful VZV vaccine and the failures of the past HSV vaccine candidates.

  • Galea, S.A., Sweet, A., Beninger, P., Steinberg, S.P., Larussa, P., Sgershon, A.A., Sharrar, R.G.: The safety profile of varicella vaccine: A 10-year review. J Inf Dis 197 (Suppl. 2), S165–S169 (2008).

    Sharrar R.G. , 'The safety profile of varicella vaccine: A 10-year review ' (2008 ) 197 J Inf Dis : S165 -S169.

    • Search Google Scholar
  • Marin, M., Meissner, H.C., Seward, J.F.: Varicella prevention in the United States: A review of successes and challenges. Pediatrics 122, e744–e752 (2008).

    Seward J.F. , 'Varicella prevention in the United States: A review of successes and challenges ' (2008 ) 122 Pediatrics : e744 -e752.

    • Search Google Scholar
  • Cohen, J.I.: Strategies for zoster vaccination in immunocompromised patients. J Infect Dis 197 (Suppl. 2), S237–S241 (2008).

    Cohen J.I. , 'Strategies for zoster vaccination in immunocompromised patients ' (2008 ) 197 J Infect Dis : S237 -S241.

    • Search Google Scholar
  • Oxman, M.N.: Zoster vaccine: Current status and future prospects. Clin Infect Dis 51, 197–213 (2010).

    Oxman M.N. , 'Zoster vaccine: Current status and future prospects ' (2010 ) 51 Clin Infect Dis : 197 -213.

    • Search Google Scholar
  • Gilden, D.: Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med 269, 496–506 (2011).

    Gilden D. , 'Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia ' (2011 ) 269 J Intern Med : 496 -506.

    • Search Google Scholar
  • Koelle, D.M., Corey, L.: Herpes simplex: Insights on pathogenesis and possible vaccines. Annu Rev Med 59, 381–395 (2008).

    Corey L. , 'Herpes simplex: Insights on pathogenesis and possible vaccines ' (2008 ) 59 Annu Rev Med : 381 -395.

    • Search Google Scholar
  • Dasgupta, G., Chentoufi, A.A., Nesburn, A.B., Wechsler, S.L., BenMohamed, L.: New con-cepts in herpes simplex virus vaccine development: Notes from the battlefield. Expert Rev Vaccines 8, 1023–1035 (2009).

    BenMohamed L. , 'New con-cepts in herpes simplex virus vaccine development: Notes from the battlefield ' (2009 ) 8 Expert Rev Vaccines : 1023 -1035.

    • Search Google Scholar
  • Johnston, C., Koelle, D.M., Wald, A.: HSV-2: In pursuit of a vaccine. J Clin Invest 121, 4600–4609 (2011).

    Wald A. , 'HSV-2: In pursuit of a vaccine ' (2011 ) 121 J Clin Invest : 4600 -4609.

  • Chentoufi, A.A., Kritzer, E., Yu, D.M., Nesburn, A.B., BenMohamed, L.: Towards a ratio-nal design of an aymptomatic clinical herpes vaccine: The old, the new and the unknown. Clin Dev Immunol 2012, Article ID 187585 (2012).

  • Gershon, A.A.: Varicella zoster vaccines and their implications for development of HSV vaccines. Virology 435, 29–36 (2013).

    Gershon A.A. , 'Varicella zoster vaccines and their implications for development of HSV vaccines ' (2013 ) 435 Virology : 29 -36.

    • Search Google Scholar
  • Roizman, B., Knipe, D.M., Whitley, R.J.: Herpes simplex viruses. In: Fields Virology. 5th edition. Edited by Knipe, D.M., Howley, P.M. Lippincott Williams & Wilkins, Philadelphia, 2007, pp. 2501–2602.

    Whitley R.J. , '', in Fields Virology , (2007 ) -.

  • Cohen, J.I., Straus, S.E., Arvin, A.M.: Varicella-zoster virus. In: Fields Virology. 5th edition. Edited by Knipe, D.M., Howley, P.M. Lippincott Williams & Wilkins, Philadelphia, 2007, pp. 2773–2818.

    Arvin A.M. , '', in Fields Virology , (2007 ) -.

  • Mueller, N.H., Gilden, D.H., Cohrs, R.J., Mahalingam, R., Nagel, M.A.: Varicella zoster virus infection: Clinical features, molecular pathogeneis of diseases, and latency. Neurol Clin 26, 675–697 (2008).

    Nagel M.A. , 'Varicella zoster virus infection: Clinical features, molecular pathogeneis of diseases, and latency ' (2008 ) 26 Neurol Clin : 675 -697.

    • Search Google Scholar
  • Gilden, D., Nagel, M.A., Mahalingam, R., Mueller, N.H., Brazeau, E.A., Pugazhenthi, S., Cohrs, R.J.: Clinical and molecular aspects of varicella zoster virus infection. Future Neurol 4, 103–117 (2009).

    Cohrs R.J. , 'Clinical and molecular aspects of varicella zoster virus infection ' (2009 ) 4 Future Neurol : 103 -117.

    • Search Google Scholar
  • Oxman, M.N.: Herpes zoster pathogenesis and cell-mediated immunity and immuno-senescence. J Am Osteopath Assoc 109, (suppl. 2): S13–S17 (2009).

    Oxman M.N. , 'Herpes zoster pathogenesis and cell-mediated immunity and immuno-senescence ' (2009 ) 109 J Am Osteopath Assoc : S13 -S17.

    • Search Google Scholar
  • Bokay, J von: Über den aetiologischen Zusammenhang der Varizellen mit gewissen Fällen von Herpes zoster. Wien Klin Woch 22, 1323–1326 (1909).

    Bokay J. , 'Über den aetiologischen Zusammenhang der Varizellen mit gewissen Fällen von Herpes zoster ' (1909 ) 22 Wien Klin Woch : 1323 -1326.

    • Search Google Scholar
  • Melroe, G.T., DeLuca, N.A., Knipe, D.M.: Herpes simplex virus 1 ha multiple mechanisms for blocking virus-induced interferon production. J Virol78, 8411–8420 (2004).

    Knipe D.M. , 'Herpes simplex virus 1 ha multiple mechanisms for blocking virus-induced interferon production ' (2004 ) 78 J Virol : 8411 -8420.

    • Search Google Scholar
  • Jerome, K.R., Fox, R., Chen, Z., Sears, A.E., Lee, H., Corey, L.: Herpes simplex virus inhib-its apoptosis through the action of two genes, US5 and US3. JVirol 73, 8950–8957 (1999).

    Corey L. , 'Herpes simplex virus inhib-its apoptosis through the action of two genes, US5 and US3 ' (1999 ) 73 JVirol : 8950 -8957.

    • Search Google Scholar
  • Perng, G.C., Jones, C.J., Ciacci-Zanella, J., Stone, M., Henderson, G.A.: Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science 287, 1500–1503 (2000).

    Henderson G.A. , 'Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript ' (2000 ) 287 Science : 1500 -1503.

    • Search Google Scholar
  • Fruh, K., Ahn, K., Djaballah, H., Sempé, P., van Endert, P.M., Tampé, R., Peterson, P.A., Yang, Y.: A viral inhibitor of peptide transporters for antigen presentation. Nature 375, 415–418 (1995).

    Yang Y. , 'A viral inhibitor of peptide transporters for antigen presentation ' (1995 ) 375 Nature : 415 -418.

    • Search Google Scholar
  • Abendroth, A., Kinchington, P.R., Slobedman, B.: Varicella zoster virus immune evasion strategies. In: Current Topics inMicrobiology and Immunology. Eds Abendroth, A., Arvin, A.M., Moffat, J.F. Springer, 2010, Vol. 342, pp. 155–171.

    Slobedman B. , 'Varicella zoster virus immune evasion strategies ' (2010 ) 342 Current Topics inMicrobiology and Immunology : 155 -171.

    • Search Google Scholar
  • Takahashi, M., Otsuka, T., Okuno, Y., Asano, Y., Yazaki, T.: Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 304, 1288–1290 (1974).

    Yazaki T. , 'Live vaccine used to prevent the spread of varicella in children in hospital ' (1974 ) 304 Lancet : 1288 -1290.

    • Search Google Scholar
  • American Academy of Pediatrics Committee on Infectious Diseases: Recommendations for the use of live attenuated varicella vaccine. Pediatrics 95, 791–796 (1995).

    'Recommendations for the use of live attenuated varicella vaccine ' (1995 ) 95 Pediatrics : 791 -796.

    • Search Google Scholar
  • Centers for Disease Control: Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mort Wkly Rep 45, 1–35 (1996).

    'Recommendations of the Advisory Committee on Immunization Practices (ACIP) ' (1996 ) 45 Morb Mort Wkly Rep : 1 -35.

    • Search Google Scholar
  • Arvin, A.M.: Varicella vaccine: Genesis, efficacy, and attenuation. Virology 284, 153–158 (2001).

    Arvin A.M. , 'Varicella vaccine: Genesis, efficacy, and attenuation ' (2001 ) 284 Virology : 153 -158.

    • Search Google Scholar
  • Takahashi, M., Asano, Y., Kamiya, H., Baba, K., Ozaki, T., Otsuka, T., Yamanishi, K.: Development of varicella vaccine. J Infect Dis 197 (Suppl. 2), 41–44 (2008).

    Yamanishi K. , 'Development of varicella vaccine ' (2008 ) 197 J Infect Dis : 41 -44.

  • Marin, M., Zhang, J.X., Seward, J.F.: Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics 128, 214 (2011).

    Seward J.F. , 'Near elimination of varicella deaths in the US after implementation of the vaccination program ' (2011 ) 128 Pediatrics : 214 -.

    • Search Google Scholar
  • Englund, J.A., Suarez, C.S., Kelly, J., Tate, D.Y., Balfour, H.H. Jr.: Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. J Pediatr 114, 37–44 (1989).

    Balfour H.H. , 'Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine ' (1989 ) 114 J Pediatr : 37 -44.

    • Search Google Scholar
  • Gomi, Y., Sunamachi, H., Takahashi, M., Yamanishi, K.: OKA varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. New Med Virol 61, 497–503 (2000).

    Yamanishi K. , 'OKA varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity ' (2000 ) 61 New Med Virol : 497 -503.

    • Search Google Scholar
  • Argaw, T., Cohen, J.I., Klutch, M., Lekstrom, K., Yoshikawa, T., Asano, Y., Krause, P.R.: Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. J Inf Dis 181, 1153–157 (2000).

    Krause P.R. , 'Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates ' (2000 ) 181 J Inf Dis : 1153 -157.

    • Search Google Scholar
  • Tillieux, S.L., Halsey, W.S., Thomas, E.S., Voycik, J.J., Sathe, G.M., Vassilev, V.: Complete DNA sequences of two OKA strain varicella-zoster virus genomes. J Virol 82, 11023–11044 (2008).

    Vassilev V. , 'Complete DNA sequences of two OKA strain varicella-zoster virus genomes ' (2008 ) 82 J Virol : 11023 -11044.

    • Search Google Scholar
  • Hardy, I., Gershon, A.A., Steinberg, S.P., LaRussa, P.: The incidence of zoster after immu-nization with live attenuated varicella vacine. A study in children with leukemia. N Eng J Med 325, 1545–1550 (1991).

    LaRussa P. , 'The incidence of zoster after immu-nization with live attenuated varicella vacine. A study in children with leukemia ' (1991 ) 325 N Eng J Med : 1545 -1550.

    • Search Google Scholar
  • Takamaya, N., Takamaya, M., Takita, J.: Herpes zoster in healthy children immunized with varicella vaccine. Pediatr Infect Dis J 19, 169–170 (2000).

    Takita J. , 'Herpes zoster in healthy children immunized with varicella vaccine ' (2000 ) 19 Pediatr Infect Dis J : 169 -170.

    • Search Google Scholar
  • Hata, A., Asanuma, H., Rinki, M., Sharp, M., Wong, R.M., Blume, K., Arvin, A.M.: Use of an inactivated varicella vaccine in recipients of hematopoetic-cell-transplants. N Eng J Med 347, 26–34 (2002).

    Arvin A.M. , 'Use of an inactivated varicella vaccine in recipients of hematopoetic-cell-transplants ' (2002 ) 347 N Eng J Med : 26 -34.

    • Search Google Scholar
  • Behrman, A., Lopez, A.S., Chaves, S.S., Watson, B.M., Schmid, D.S.: Varicella immunity in vaccinated healthcare workers. J Clin Virol 57, 109–114 (2013).

    Schmid D.S. , 'Varicella immunity in vaccinated healthcare workers ' (2013 ) 57 J Clin Virol : 109 -114.

    • Search Google Scholar
  • Centers for Disease Control, 2012. Vaccines and Preventable diseases: Varicella (chickenpox) vaccination. http://www.cdc.gov/vaccines/vpd-vac/varicella/

    '', in Vaccines and Preventable diseases: Varicella (chickenpox) vaccination , (2012 ) -.

  • Brisson, M., Gay, N.J., Edmunds, W.J., Andrews, N.J.: Exposure to varicella boosts immu-nity to herpes-zoster: Implications for mass vaccination against chickenpox. Vaccine 20, 2500–2507 (2002).

    Andrews N.J. , 'Exposure to varicella boosts immu-nity to herpes-zoster: Implications for mass vaccination against chickenpox ' (2002 ) 20 Vaccine : 2500 -2507.

    • Search Google Scholar
  • Mitka, M.: FDA approves shingles vaccine: Herpes zoster vaccine targets older adults. JAMA 296, 157–158 (2006).

    Mitka M. , 'FDA approves shingles vaccine: Herpes zoster vaccine targets older adults ' (2006 ) 296 JAMA : 157 -158.

    • Search Google Scholar
  • Oxman, M.N., Levin, M.J., Johnson, G.R., Schmader, K.E., Straus, S.E., Gelb, L.D., Arbeit, R.D., Simberkoff, M.S., Gershon, A.A., Davis, L.E., Weinberg, A., Boardman, K.D., Williams, H.M., Hongyuan Zhang, J., Peduzzi, P.N., Beisel, C.E., Morrison, V.A., Guatelli, J.C., Brooks, P.A., Kauffman, C.A., Pachucki, C.T., Neuzil, K.M., Betts, R.F., Wright, P.F., Griffin, M.R., Brunell, P., Soto, N.E., Marques, A.R., Keay, S.K., Goodman, R.P., Cotton, D.J., Gnann, J.W. Jr., Loutit, J., Holodniy, M., Keitel, W.A., Crawford, G.E., Yeh, S.-S., Lobo, Z., Toney, J.F., Greenberg, R.N., Keller, P.M., Harbecke, R., Hayward, A.R., Irwin, M.R., Kyriakides, T.C., Chan, C.Y., Chan, I.S.F., Wang, W.W.B., Annunziato, P.W., Silber, J.L.: Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Eng J Med 352, 2271–2284 (2005).

    Silber J.L. , 'Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults ' (2005 ) 352 N Eng J Med : 2271 -2284.

    • Search Google Scholar
  • Harpaz, R., Ismael, R., Sanchez, O., Seward, J.F.: Prevention of herpes zoster. Recommendation of the Advisory Committee on Immunization Practices (ACIP). Center for Disease Control and Prevention, Recommendations and Reports 57, 1–30 (2008).

    Seward J.F. , 'Prevention of herpes zoster. Recommendation of the Advisory Committee on Immunization Practices (ACIP) ' (2008 ) 57 Center for Disease Control and Prevention, Recommendations and Reports : 1 -30.

    • Search Google Scholar
  • Schmader, K.E., Levin, M.J., Gnann, J.W. Jr., McNeil, S.A., Vesikari, T., Betts, R.F., Keay, S., Stek, J.E., Bundick, N.D., Su, S.C., Zhao, Y., Li, X., Chan, I.S.F., Annunziato, P.W., Parrino, J.: Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 54(7), 922–928 (2012).

    Parrino J. , 'Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years ' (2012 ) 54 Clin Infect Dis : 922 -928.

    • Search Google Scholar
  • Chen, J.J., Zhu, Z., Gershon, A.A., Gershon, M.D.: Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell 119, 915–926 (2004).

    Gershon M.D. , 'Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster ' (2004 ) 119 Cell : 915 -926.

    • Search Google Scholar
  • Cohen, J.: Painful failure of promising genital herpes vaccine. Science 330(6002), 304 (2010).

    Cohen J. , 'Painful failure of promising genital herpes vaccine ' (2010 ) 330 Science : 304 -.

    • Search Google Scholar
  • Gonczol, E., Plotkin, S.: Development of a cytomegalovirus vaccine: Lessons from recent clinical trials. Expert Opin Biol Ther 1, 401–412 (2001).

    Plotkin S. , 'Development of a cytomegalovirus vaccine: Lessons from recent clinical trials ' (2001 ) 1 Expert Opin Biol Ther : 401 -412.

    • Search Google Scholar
  • Plotkin, S.A.: Vaccines: Past, present and future. Nature Med 11, S5–S11 (2005).

    Plotkin S.A. , 'Vaccines: Past, present and future ' (2005 ) 11 Nature Med : S5 -S11.

  • Bernstein, D.I.: Vaccines for cytomegalovirus. Infect Disord Drug Targets 11, 514–525 (2011).

    Bernstein D.I. , 'Vaccines for cytomegalovirus ' (2011 ) 11 Infect Disord Drug Targets : 514 -525.

    • Search Google Scholar
  • Griffiths, P., Plotkin, S., Mocarski, E., Pass, R., Schleiss, M., Krause, P., Bialek, S.: Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 31, Suppl. 2:B 197–203 (2013).

    Bialek S. , 'Desirability and feasibility of a vaccine against cytomegalovirus ' (2013 ) 31 Vaccine : 197 -203.

    • Search Google Scholar
  • Gorse, G.J., Falsey, A.R., Fling, J.A., Poling, T.L., Strout, C.B., Tsang, P.H.: Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18–64 years of age. Vaccine 31(19), 2358–2365 (2013).

    Tsang P.H. , 'Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18–64 years of age ' (2013 ) 31 Vaccine : 2358 -2365.

    • Search Google Scholar
All Time Past Year Past 30 Days
Abstract Views 31 31 4
Full Text Views 4 2 0
PDF Downloads 0 0 0